Sign inJoin waitlistJoin the waitlist

Cheilonda Johnson

Co-Program Director, Postdoc T32 · University of Pennsylvania Health System

Credentials: · · · · · · ·

History

Postdoc T32 · University of Pennsylvania Health System
Present

MHS Health Science Johns Hopkins Bloomberg School of Public Health 2011
2011
Pulmonary Disease and Critical Care Medicine
Johns Hopkins Hospital
2007–2010
Internal Medicine
Massachusetts General Hospital
2004–2007
Perelman School of Medicine at the University of Pennsylvania
2000–2004

Research

A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12…
Rheumatology · 2017 · 179 citations
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune…
Arthritis & Rheumatology · 2024 · 174 citations
Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients
Arthritis Care & Research · 2017 · 140 citations

Sonye Danoff
24 papers
Andrew Mammen
13 papers
Lisa Christopher-Stine
13 papers
Jemima Albayda
11 papers · 4 as a fellow
Julie Paik
11 papers
IP
Iago Pinal-Fernandez
10 papers
Joyce Lee
7 papers
Michael George
7 papers
Didem Saygin
6 papers
Elana Bernstein
6 papers
Jake Natalini
6 papers · 2 as a fellow
John Kim
6 papers · 6 as a resident

Grants

CTSA Postdoctoral T32 at the University of Pennsylvania
National Center for Advancing Translational Sciences · T32
PI · $532.7K · University of Pennsylvania
2026–2031
Myositis-ILD Risk Prediction Models and Endotypes
National Heart, Lung, and Blood Institute · R01
Contact PI · $1.5M · University of Pennsylvania
2024–2028
Determinants of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease.
National Heart, Lung, and Blood Institute · K01
Contact PI · $924K · University of Pennsylvania
2017–2023